pulmonologyadvisor3h
Cystic Fibrosis: GI Symptom Relief From ETI Wanes Over Long Term
In adults with cystic fibrosis, gastrointestinal symptoms initially improve with ETI but most do not consistently improve with longer-term use.
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
BioSpace1d
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
FierceBiotech1d
Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Everything to know about cystic fibrosis and what causes it
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
thorax.bmj2d
Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by CFTR modulators
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
emjreviews.com3d
Vascular Changes and Fibrosis Progression in Liver Disease
Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...
U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week
Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.